Review
Immunology
Jason Cheung, Beata Zahorowska, Michael Suranyi, Jeffrey K. W. Wong, Jason Diep, Stephen T. T. Spicer, Nirupama D. D. Verma, Suzanne J. Hodgkinson, Bruce M. M. Hall
Summary: The immune response to an allograft can activate lymphocytes that cause rejection. The activation of T regulatory cells can reduce allograft rejection and induce immune tolerance. Activated T regulatory cells can be distinguished by various markers. A more detailed characterization of these cells may help reduce non-specific immunosuppression.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Jessica G. Lee, Kathleen E. Jaeger, Yoichi Seki, Yi Wei Lim, Christina Cunha, Aleksandra Vuchkovska, Alexander J. Nelson, Anya Nikolai, Dan Kim, Michael Nishimura, Katherine L. Knight, Paula White, Makio Iwashima
Summary: The study reveals that a subset of CD14(+) monocytes can generate regulatory Foxp3(+) T-bet(+) T cells from umbilical cord blood, which suppress T-cell proliferation and ameliorate graft-versus-host disease. Additionally, adult peripheral blood monocytes are capable of inducing Foxp3(+) T cells, but their induction is inhibited by lymphoid cells from adult peripheral blood in neonates. This suggests a novel immunoregulatory role of monocytes in generating regulatory T cells with implications for both neonates and adults.
Article
Biology
Severine Menoret, Laurent Tesson, Severine Remy, Victor Gourain, Celine Serazin, Claire Usal, Aude Guiffes, Vanessa Chenouard, Laure-Helene Ouisse, Malika Gantier, Jean-Marie Heslan, Cynthia Fourgeux, Jeremie Poschmann, Carole Guillonneau, Ignacio Anegon
Summary: In this study, a Foxp3-EGFP rat transgenic line was created to genetically tag CD4(+) and CD8(+) FOXP3(+) regulatory T cells. CD4(+)EGFP(+) Treg were found to be 5-10 times more frequent than CD8(+)EGFP(+) Treg. RNAseq analysis provided insights into the transcriptome of CD8(+) Treg, allowing for a better understanding of their phenotype and function.
Article
Immunology
Jierui Wang, Yu Zhang, Minjin Wang, Yan Ren, Meng Tang, Ling Liu, Dong Zhou
Summary: This study compared the efficacy of intravenous immunoglobulin (IVIG) combined with antiretroviral therapy (ART) versus ART alone in patients with HIV-associated Guillain-Barre syndrome (GBS). The results showed that patients in the IVIG + ART group had significantly lower GBS disability scale grades compared to those in the ART alone group. Moreover, a higher proportion of patients in the IVIG + ART group were able to walk independently after four weeks of treatment.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Immunology
Jingnan Liao, Yuan Li, Xiaofeng Li, Xian Su, Jing Peng, Na Xiao, Xiangxiu Fan, Huijun Chen, Guangxiu Lu, Ge Lin, Lamei Cheng, Fei Gong
Summary: The study found that pre-pregnancy blood Treg levels were significantly lower in URPL patients than in controls, and that Treg levels predicted subsequent miscarriages. There were no significant differences among other blood cell types between the two groups.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Immunology
Michal P. Kuczma, Edyta A. Szurek, Anna Cebula, Vu L. Ngo, Maciej Pietrzak, Piotr Kraj, Timothy L. Denning, Leszek Ignatowicz
Summary: The study suggests that T cell anergy induction plays a crucial role in maintaining the balance of self-immunity. Disruption in peripherally-induced Tregs formation or exposure to selective self-peptides can result in an accumulation of anergic cells. Additionally, microbial antigens can induce anergy and promote the conversion of naive T cells to regulatory T cells.
MUCOSAL IMMUNOLOGY
(2021)
Article
Immunology
Bruce M. Hall, Rachael M. Hall, Giang T. Tran, Catherine M. Robinson, Paul L. Wilcox, Prateek K. Rakesh, Chuanmin Wang, Alexandra F. Sharland, Nirupama D. Verma, Suzanne J. Hodgkinson
Summary: The CD4(+)CD25(+)Foxp3(+)T cell population is heterogeneous, consisting of three major subgroups with different functions and characteristics. Treatment with rIL-5 can prevent rejection of transplants by activating Ts2 cells and Th2-like Treg. This therapeutic approach significantly improves survival rates and reduces rejection reactions.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Medicine, General & Internal
Anetta Lasek-Bal, Anna Wagner-Kusz, Barbara Rogoz, Malgorzata Cisowska-Babraj, Gabriela Gajewska
Summary: This study evaluated the efficacy and safety of IVIg in patients with selected nervous system diseases. The results showed that IVIg can lead to neurological improvement in patients with myasthenia gravis and Guillain-Barre syndrome, and disease stabilisation in patients with neuromyelitis optica spectrum disorder and chronic inflammatory demyelinating polyneuropathy. The study confirmed the improved safety of IVIg for selected neurological diseases.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Immunology
Matthew E. Brown, Leeana D. Peters, Seif R. Hanbali, Juan M. Arnoletti, Lindsey K. Sachs, Kayla Q. Nguyen, Emma B. Carpenter, Howard R. Seay, Christopher A. Fuhrman, Amanda L. Posgai, Melanie R. Shapiro, Todd M. Brusko
Summary: This study found that isolating Tregs using a CD4(+)CD25(+)CD226(-) strategy leads to a population with increased purity, lineage stability, and suppressive capabilities, which may be beneficial for the treatment of autoimmune diseases.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Sander J. van Tilburg, Bart C. Jacobs, Pleuni Ooijevaar-de Heer, Willem-Jan R. Fokkink, Ruth Huizinga, Gestur Vidarsson, Theo Rispens
Summary: This study developed novel ELISAs to specifically monitor the pharmacokinetics of IVIg, utilizing polymorphic determinants G1m(a), G1m(x), and G1m(f). The assays can discriminate between endogenous IgG and therapeutic polyclonal IgG, providing insights into the variability of IVIg pharmacokinetics.
EUROPEAN JOURNAL OF IMMUNOLOGY
(2022)
Article
Clinical Neurology
Patricia Faustino, Maria Coutinho, Marisa Brum, Luisa Medeiros, Filipa Ladeira
Summary: The benefit of a second treatment cycle in patients with Guillain-Barré Syndrome (GBS) remains unproven. This study compared the prognosis of GBS patients treated with one or two cycles of intravenous immunoglobulin (IVIg) or plasma exchange (PE). The results showed that the two-cycle treatment did not lead to improvement in GBS-DS or other clinical outcomes.
JOURNAL OF THE NEUROLOGICAL SCIENCES
(2022)
Article
Clinical Neurology
Patricia Faustino, Maria Coutinho, Marisa Brum, Luisa Medeiros, Filipa Ladeira
Summary: This study aimed to compare the prognosis of GBS patients treated with one or two cycles of IVIg or PE. The results showed that there was no significant benefit in terms of GBS-DS improvement, need for intensive care unit, or mechanical invasive ventilation in patients treated with two cycles compared to those treated with one cycle.
JOURNAL OF THE NEUROLOGICAL SCIENCES
(2022)
Article
Clinical Neurology
Delia Gagliardi, Irene Faravelli, Manuel Alfredo Podesta, Roberta Brusa, Eleonora Mauri, Domenica Saccomanno, Alessio Di Fonzo, Sara Bonato, Elio Scarpini, Nereo Bresolin, Giacomo Pietro Comi, Stefania Corti
Summary: This study found a significant independent association between baseline serum sodium levels and severe disability at discharge in GBS patients, and also noted that hyponatremia was more frequently observed after treatment with intravenous immune globulin (IVIG), suggesting dilutional pseudohyponatremia as a probable cause.
FRONTIERS IN NEUROLOGY
(2021)
Article
Oncology
Renyong Wang, Ruixue Li, Tiehan Li, Lei Zhu, Zongze Qi, Xiaokui Yang, Huan Wang, Baoquan Cao, Hong Zhu
Summary: Bone marrow mesenchymal stem cells (BMSCs) have the potential to treat immune-related diseases by releasing exosomes. These exosomes contain a microRNA called miR-181a which can be transferred to CD4(+) T cells. In CD4(+) cells, miR-181a suppresses the expression of SIRT1, leading to increased levels of FOXP3 through protein acetylation. This study highlights the critical role of BMSC-derived exosomal miR-181a in maintaining immune tolerance through the induction of Treg cells.
JOURNAL OF ONCOLOGY
(2022)
Review
Immunology
Min Hu, Natasha M. Rogers, Jennifer Li, Geoff Y. Zhang, Yuan Min Wang, Karli Shaw, Philip J. O'Connell, Stephen Alexander
Summary: Tregs play a crucial role in kidney transplantation by limiting immune activation and potentially reducing the need for immunosuppression. Studies have shown their importance in improving allo-specific Treg function in both animal and human models.
FRONTIERS IN IMMUNOLOGY
(2021)
